Estudo randomizado de fase 2 | Baxdrostate para hipertensão resistente a tratamento

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link para o resumo – $ para texto completo)

Comentário: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension – BrigHTN – American College of Cardiology

Comentário no Twitter (fio – clique para saber mais)

Aldosterone has long been a pharmacologic target for the treatment of hypertension. However, a new small-molecule drug called baxdrostat inhibits aldosterone synthase in patients with treatment-resistant hypertension. 1/14 pic.twitter.com/F27WE4Wa1d

— NEJM (@NEJM) February 3, 2023